Patient Outcomes in Data-Driven SCD Care: Evidence from Tracka Deployments
How data-driven patient tracking improves sickle cell disease outcomes — evidence showing reduced hospitalizations, better adherence, and improved retention.
Executive Summary
This report presents outcome data from Tracka deployments across Nigeria, analyzing the impact of structured digital patient tracking on SCD care. Across 342 facilities and over 12,800 patients, hydroxyurea adherence increased from 42% to 78% after 12 months, ED visits decreased by 35%, the proportion of patients with up-to-date labs increased from 28% to 71%, and programs achieved a 92% 12-month retention rate compared to historical 50-60% for paper-based programs. These findings provide compelling evidence that digital tracking directly translates to better outcomes.
Key Findings
Hydroxyurea adherence increased from 42% at baseline to 78% after 12 months of structured tracking with field agent follow-up.
Emergency department visits for pain crises decreased by 35% among patients with consistent tracking and proactive monitoring.
Patients with up-to-date monitoring labs increased from 28% to 71% through automated reminders and field agent engagement.
Programs using Tracka achieved 92% 12-month retention, compared to historical 50-60% for paper-based programs.
Study Design
Analysis uses programmatic data from 342 facilities across 24 Nigerian states where Tracka was deployed between 2024 and 2026. Includes all patients with at least 6 months follow-up (n=12,847). Pre-post design comparing baseline (first month) to subsequent quarterly periods. Key outcomes: hydroxyurea adherence (MCV trends and refill tracking), healthcare utilization, monitoring compliance, and retention in care.
Hydroxyurea Adherence
At baseline, only 42% of eligible patients demonstrated consistent adherence. Through automated reminders, regular field agent visits, and clinician alerts for non-adherent patients, adherence increased to 78% by month 12. The improvement was most pronounced with high-performing field agents. The highest adherence quartile showed mean HbF of 19.2% versus 8.7% in the lowest, and 1.3 versus 4.2 pain crises per year — demonstrating that tracking-supported adherence improvements produce real clinical benefits.
Healthcare Utilization
ED visits decreased 35% and hospitalizations 28% between Q1 and Q4 of tracking, driven by fewer pain crises (consistent with better adherence) and earlier complication identification through regular monitoring. Based on average hospitalization costs of $150-400 in Nigerian settings, reduced hospitalizations represent savings of approximately $180 per patient per year — more than offsetting tracking program costs, supporting the economic case for investment.
Monitoring Compliance
Patients with up-to-date labs increased from 28% to 71% through automated visit scheduling incorporating lab due dates, field agent prompting during home visits, and facility performance dashboards creating accountability. This improvement directly supports safer hydroxyurea management and earlier detection of organ complications.
Patient Retention
Programs achieved 92% 12-month retention versus historical 50-60% for paper-based programs. Proactive identification of at-risk patients through automated missed-visit flags, field agent outreach, and simplified scheduling drove this improvement. Among the 8% lost, reasons were relocation (42%), death (18%), transfer to non-Tracka facilities (23%), and unknown (17%).
Conclusions
Structured digital tracking combined with community-based field engagement produces transformative improvements in SCD care: 36 percentage points in adherence, 35% reduction in emergency visits, and 92% retention. As programs scale, the growing longitudinal dataset will enable increasingly sophisticated outcome analyses, further informing clinical practice and health policy across Africa.
Download the full report
Enter your email to receive the complete “Patient Outcomes in Data-Driven SCD Care: Evidence from Tracka Deployments” report as a downloadable PDF.